These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 21978160)
1. Evaluation of anti-influenza efficiency of polyclonal IgG antibodies specific to the ectodomain of M2 protein of influenza A virus by passive immunization of mice. Király J; Varečková E; Mucha V; Kostolanský F Acta Virol; 2011; 55(3):261-5. PubMed ID: 21978160 [TBL] [Abstract][Full Text] [Related]
2. Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein. Staneková Z; Király J; Stropkovská A; Mikušková T; Mucha V; Kostolanský F; Varečková E Acta Virol; 2011; 55(1):61-7. PubMed ID: 21434706 [TBL] [Abstract][Full Text] [Related]
3. Antiserum against the conserved nine amino acid N-terminal peptide of influenza A virus matrix protein 2 is not immunoprotective. De Filette M; Ysenbaert T; Roose K; Schotsaert M; Roels S; Goossens E; Schepens B; Fiers W; Saelens X J Gen Virol; 2011 Feb; 92(Pt 2):301-6. PubMed ID: 20965983 [TBL] [Abstract][Full Text] [Related]
4. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. El Bakkouri K; Descamps F; De Filette M; Smet A; Festjens E; Birkett A; Van Rooijen N; Verbeek S; Fiers W; Saelens X J Immunol; 2011 Jan; 186(2):1022-31. PubMed ID: 21169548 [TBL] [Abstract][Full Text] [Related]
5. Passively transferred M2e-specific monoclonal antibody reduces influenza A virus transmission in mice. Kolpe A; Schepens B; Ye L; Staeheli P; Saelens X Antiviral Res; 2018 Oct; 158():244-254. PubMed ID: 30179634 [TBL] [Abstract][Full Text] [Related]
6. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Fan J; Liang X; Horton MS; Perry HC; Citron MP; Heidecker GJ; Fu TM; Joyce J; Przysiecki CT; Keller PM; Garsky VM; Ionescu R; Rippeon Y; Shi L; Chastain MA; Condra JH; Davies ME; Liao J; Emini EA; Shiver JW Vaccine; 2004 Aug; 22(23-24):2993-3003. PubMed ID: 15297047 [TBL] [Abstract][Full Text] [Related]
7. Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin. Stepanova LA; Kotlyarov RY; Kovaleva AA; Potapchuk MV; Korotkov AV; Sergeeva MV; Kasianenko MA; Kuprianov VV; Ravin NV; Tsybalova LM; Skryabin KG; Kiselev OI PLoS One; 2015; 10(3):e0119520. PubMed ID: 25799221 [TBL] [Abstract][Full Text] [Related]
8. Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice. Lu J; Guo Z; Pan X; Wang G; Zhang D; Li Y; Tan B; Ouyang L; Yu X Respir Res; 2006 Mar; 7(1):43. PubMed ID: 16553963 [TBL] [Abstract][Full Text] [Related]
9. In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran. Ebrahimi SM; Dabaghian M; Tebianian M; Jazi MH Virology; 2012 Aug; 430(1):63-72. PubMed ID: 22595444 [TBL] [Abstract][Full Text] [Related]
10. IgG subclass response and protection against challenge following immunisation of mice with various influenza A vaccines. Ben-Ahmeida ET; Potter CW; Gregoriadis G; Adithan C; Jennings R J Med Microbiol; 1994 Apr; 40(4):261-9. PubMed ID: 8151677 [TBL] [Abstract][Full Text] [Related]
11. Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge. Galarza JM; Latham T; Cupo A Viral Immunol; 2005; 18(2):365-72. PubMed ID: 16035948 [TBL] [Abstract][Full Text] [Related]
12. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus. Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096 [TBL] [Abstract][Full Text] [Related]
13. Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules. Tamura S; Funato H; Hirabayashi Y; Suzuki Y; Nagamine T; Aizawa C; Kurata T Eur J Immunol; 1991 Jun; 21(6):1337-44. PubMed ID: 1646112 [TBL] [Abstract][Full Text] [Related]
14. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. Jegerlehner A; Schmitz N; Storni T; Bachmann MF J Immunol; 2004 May; 172(9):5598-605. PubMed ID: 15100303 [TBL] [Abstract][Full Text] [Related]
15. A lipopeptide based on the M2 and HA proteins of influenza A viruses induces protective antibody. Pejoski D; Zeng W; Rockman S; Brown LE; Jackson DC Immunol Cell Biol; 2010 Jul; 88(5):605-11. PubMed ID: 20177411 [TBL] [Abstract][Full Text] [Related]
16. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235 [TBL] [Abstract][Full Text] [Related]
17. Reduced protection of RIPK3-deficient mice against influenza by matrix protein 2 ectodomain targeted active and passive vaccination strategies. Oltean T; Ibanez LI; Divert T; Ysenbaert T; Van Eeckhoutte H; Goossens V; Schotsaert M; Bracke K; Schepens B; Maelfait J; Takahashi N; Saelens X; Vandenabeele P Cell Death Dis; 2022 Mar; 13(3):280. PubMed ID: 35351865 [TBL] [Abstract][Full Text] [Related]
18. Co-immunization with tandem repeat heterologous M2 extracellular proteins overcomes strain-specific protection of split vaccine against influenza A virus. Lee YN; Kim MC; Lee YT; Kim YJ; Lee J; Kim C; Ha SH; Kang SM Antiviral Res; 2015 Oct; 122():82-90. PubMed ID: 26248203 [TBL] [Abstract][Full Text] [Related]
19. Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs. Chen Z; Matsuo K; Asanuma H; Takahashi H; Iwasaki T; Suzuki Y; Aizawa C; Kurata T; Tamura S Vaccine; 1999 Feb; 17(7-8):653-9. PubMed ID: 10067670 [TBL] [Abstract][Full Text] [Related]
20. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. Renegar KB; Small PA; Boykins LG; Wright PF J Immunol; 2004 Aug; 173(3):1978-86. PubMed ID: 15265932 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]